Breaking News Instant updates and real-time market news.

BIOS

BioScrip

$2.86

0.085 (3.06%)

09:05
07/22/19
07/22
09:05
07/22/19
09:05

BioScrip says ISS, Glass Lewis recommend voting for proposals tied to merger

BioScrip announced that Institutional Shareholder Services and Glass, Lewis & Co. recommend that BioScrip stockholders vote "FOR" the proposals that are conditions to the proposed merger with Option Care, at the special meeting of stockholders to be held on August 2, 2019. BioScrip's Board of Directors encourages stockholders to vote "FOR" each of the proposals relating to the combination with Option Care. The merger is expected to close in early August 2019 after the special meeting of stockholders.

  • 12

    Sep

  • 13

    Nov

BIOS BioScrip
$2.86

0.085 (3.06%)

03/18/19
LSCM
03/18/19
NO CHANGE
Target $3.5
LSCM
Buy
BioScrip outlook positive following 'unexpected' merger, say Lake Street
Lake Street analyst Brooks O'Neil says BioScrip's outlook remains positive despite Friday's "disappointing" Q4 results and "unexpected" all-stock merger with Option Care. The combined company can deliver high single digit revenue growth and in the range of $175M of 2019 adjusted EBITDA pre- synergies, O'Neil tells investors in a research note. Further, while management has committed to $60M of synergies, the analyst thinks "there could be much more, certainly over several years." His analysis can get to a $3.50 per share valuation for BioScrip "without stretching too far." O'Neil keeps a Buy rating on the stock with a $3.50 price target.
03/18/19
03/18/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Hold from Buy at Needham with analyst Laura Martin citing three factors that she sees creating a "negative network effect," namely its strategic pivot toward privacy and encrypted messages, the growing risks of regulation and "horrific" events like those recently in New Zealand that hurt Facebook's brand and are difficult to block from the service at a 100% level. 2. Quest Diagnostics (DGX) downgraded to Neutral from Outperform at Credit Suisse. 3. Aramark (ARMK) downgraded to Neutral from Buy at Nomura Instinet with analyst Dan Dolev saying while the company's "significant scale" in North America should drive consistent 5%-plus organic growth, "execution mishaps and inability to win sufficient new business" resulted in just 2%-3% organic growth versus 7%-8% for main competitor Compass. 4. BioScrip (BIOS) downgraded to Equal Weight from Overweight at Stephens with analyst Dana Hambly saying the company "surprised the market" by announcing a merger with Option Care. 5. PVH Corp. (PVH) assumed with a Neutral from Buy at Citi with analyst Paul Lejuez saying while PVH has two brands with good global growth potential in Tommy Hilfiger and Calvin Klein, the company overall is still heavily dependent on the North America wholesale and outlet channels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/18/19
ADAM
03/18/19
NO CHANGE
Target $3.5
ADAM
Buy
Canaccord, while disappointed with merger terms, remains buyer of BioScrip
Canaccord Genuity analyst Richard Close lowered his price target for BioScrip to $3.50 from $5.00 while reiterating a Buy rating on the shares. While disappointed with the terms of the Option Care merger agreement as BioScrip shareholders are just 20% shareholders post-transaction, the analyst says he understands the rationale for the merger. The need for scale in healthcare is "increasingly paramount as the provider and payer markets consolidate and reimbursement risk is always present," Close tells investors in a research note titled "Merger: short-term pain but long-term." Longer-term scale matters and the transaction provides an improved capital structure, says the analyst. He remains a buyer of BioScrip shares.
07/15/19
LSCM
07/15/19
NO CHANGE
Target $4.5
LSCM
Buy
CMS funding potential 'meaningful positive' for BioScrip, says Lake Street
The Centers for Medicare & Medicaid Services last week included in its budget proposal funding for the new Medicare home infusion benefit for 2021, Lake Street analyst Brooks O'Neil tells investors in a research note. The Cures Act in 2016 created the benefit for all eligible seniors, and now CMS is acknowledging it exists and providing funding for it in the Medicare budget, adds the analyst. He believes this is a potentially "meaningful positive" for BioScrip as Medicare currently does not reimburse for home infusion services and the senior population will likely become a heavy user of such services. O'Neil affirms a Buy rating on the shares with a $4.50 price target.

TODAY'S FREE FLY STORIES

EXAS

Exact Sciences

$104.03

0.66 (0.64%)

05:56
09/23/19
09/23
05:56
09/23/19
05:56
Hot Stocks
Exact Sciences says Cologuard gains FDA approval for use in ages 45-49 »

Exact Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

APTV

Aptiv

$87.10

-2.41 (-2.69%)

, HYMTF

Hyundai Motor

$0.00

(0.00%)

05:53
09/23/19
09/23
05:53
09/23/19
05:53
Hot Stocks
Aptiv, Hyundai Motor to form autonomous driving JV »

Aptiv (APTV) and Hyundai…

APTV

Aptiv

$87.10

-2.41 (-2.69%)

HYMTF

Hyundai Motor

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RKDA

Arcadia Biosciences

$5.29

-0.23 (-4.17%)

05:47
09/23/19
09/23
05:47
09/23/19
05:47
Hot Stocks
Arcadia Biosciences granted U.S. patent for reduced gluten GoodWheat »

Arcadia Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLVS

Clovis

$4.76

-0.1 (-2.06%)

05:38
09/23/19
09/23
05:38
09/23/19
05:38
Hot Stocks
Clovis acquires rights to FAP »

Clovis Oncology has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

TRV

Travelers

$146.32

-0.69 (-0.47%)

05:37
09/23/19
09/23
05:37
09/23/19
05:37
Hot Stocks
Travelers receives approval to transfer European business to Dublin »

Travelers announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

DEA

Easterly Government Properties

$20.96

0.02 (0.10%)

05:37
09/23/19
09/23
05:37
09/23/19
05:37
Initiation
Easterly Government Properties initiated  »

Easterly Government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

TEL

TE Connectivity

$93.21

-1.21 (-1.28%)

05:34
09/23/19
09/23
05:34
09/23/19
05:34
Downgrade
TE Connectivity rating change  »

TE Connectivity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWDBY

Swedbank

$0.00

(0.00%)

05:33
09/23/19
09/23
05:33
09/23/19
05:33
Upgrade
Swedbank rating change  »

Swedbank upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESLOY

EssilorLuxottica

$0.00

(0.00%)

05:32
09/23/19
09/23
05:32
09/23/19
05:32
Upgrade
EssilorLuxottica rating change  »

EssilorLuxottica upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWY

Chewy

$26.44

-1.06 (-3.85%)

05:30
09/23/19
09/23
05:30
09/23/19
05:30
Upgrade
Chewy rating change  »

Chewy upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEXAY

Atos

$0.00

(0.00%)

05:29
09/23/19
09/23
05:29
09/23/19
05:29
Upgrade
Atos rating change  »

Atos upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$238.80

3.2 (1.36%)

05:28
09/23/19
09/23
05:28
09/23/19
05:28
Hot Stocks
Biogen says Plegridy, Avonex receive 'positive opinion' from CHMP »

Biogen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ACN

Accenture

$192.99

-1.78 (-0.91%)

05:28
09/23/19
09/23
05:28
09/23/19
05:28
Initiation
Accenture initiated  »

Accenture initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

TELDF

Telefonica Deutschland

$0.00

(0.00%)

05:27
09/23/19
09/23
05:27
09/23/19
05:27
Upgrade
Telefonica Deutschland rating change  »

Telefonica Deutschland…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGY

VAALCO Energy

$2.08

0.06 (2.97%)

05:26
09/23/19
09/23
05:26
09/23/19
05:26
Initiation
VAALCO Energy initiated  »

VAALCO Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$11.64

-0.565 (-4.63%)

05:25
09/23/19
09/23
05:25
09/23/19
05:25
Hot Stocks
PG&E expects to turn off power late Monday in nine CA counties due to fire risk »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Oct

  • 10

    Nov

  • 10

    Nov

  • 07

    Jan

AIBRF

AIB Group

$0.00

(0.00%)

05:25
09/23/19
09/23
05:25
09/23/19
05:25
Upgrade
AIB Group rating change  »

AIB Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAOFY

Tatneft

$0.00

(0.00%)

05:22
09/23/19
09/23
05:22
09/23/19
05:22
Downgrade
Tatneft rating change  »

Tatneft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESYJY

easyJet

$0.00

(0.00%)

05:21
09/23/19
09/23
05:21
09/23/19
05:21
Upgrade
easyJet rating change  »

easyJet upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLOWY

Vallourec

$0.00

(0.00%)

05:20
09/23/19
09/23
05:20
09/23/19
05:20
Downgrade
Vallourec rating change  »

Vallourec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TELNY

Telenor

$0.00

(0.00%)

05:15
09/23/19
09/23
05:15
09/23/19
05:15
Downgrade
Telenor rating change  »

Telenor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANNSF

Aena

$0.00

(0.00%)

05:14
09/23/19
09/23
05:14
09/23/19
05:14
Downgrade
Aena rating change  »

Aena downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.69

-3.22 (-1.46%)

05:13
09/23/19
09/23
05:13
09/23/19
05:13
Recommendations
Apple analyst commentary  »

Piper survey shows higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DXCM

DexCom

$154.45

-0.49 (-0.32%)

, ABT

Abbott

$83.56

0.35 (0.42%)

05:04
09/23/19
09/23
05:04
09/23/19
05:04
Recommendations
DexCom, Abbott analyst commentary  »

DexCom remains a…

DXCM

DexCom

$154.45

-0.49 (-0.32%)

ABT

Abbott

$83.56

0.35 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 16

    Oct

  • 13

    Nov

EW

Edwards Lifesciences

$219.56

4.45 (2.07%)

04:58
09/23/19
09/23
04:58
09/23/19
04:58
Initiation
Edwards Lifesciences initiated  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.